<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="13312">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01947907</url>
  </required_header>
  <id_info>
    <org_study_id>ACP-001_CT-004</org_study_id>
    <nct_id>NCT01947907</nct_id>
  </id_info>
  <brief_title>Safety, PK/PD and Efficacy of ACP-001 Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)</brief_title>
  <official_title>A Multicenter, Phase 2, Randomized, Open Label, Active-controlled, Parallel-group Study Investigating the Safety, Tolerability, and Efficacy of Different Dose Levels of ACP-001 Administered Once Weekly Versus Standard Daily rhGH Replacement Therapy in Pre-pubertal Children With Growth Hormone Deficiency (GHD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ascendis Pharma A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ascendis Pharma A/S</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>Hungary: Ministry of Health, Social and Family Affairs</authority>
    <authority>Czech Republic: State Institute for Drug Control</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A six month study of ACP-001, a long-acting growth hormone product, versus standard human
      growth hormone therapy. ACP-001 will be given once-a-week, standard human growth hormone
      (hGH) will be given on a daily basis. The primary aim is to demonstrate safety,
      pharmacokinetics and pharmacodynamics over a period of six months. A secondary objective is
      the comparison of height velocity (HV) of the ACP-001 treated groups to the daily hGH
      treatment group.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety of ACP-001 on different dosing levels</measure>
    <time_frame>26 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number of adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of ACP-001</measure>
    <time_frame>26 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pharmacokinetic assessment of ACP-001 by AUC</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IGF-I response</measure>
    <time_frame>26 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>IGF-I levels and change in IGF-I levels over a period of 26 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Local tolerability  of ACP-001</measure>
    <time_frame>26 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number of injection site reactions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of ACP-001 on different dosing levels</measure>
    <time_frame>26 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Incidence of anti-hGH antibodies</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Height velocity</measure>
    <time_frame>26 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Height velocity over a period of 26 weeks (annualized)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Growth Hormone Deficiency (GHD)</condition>
  <arm_group>
    <arm_group_label>ACP-001, dose-level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once weekly subcutaneous injection of ACP-001</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACP-001, dose-level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once weekly subcutaneous injection of ACP-001</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACP-001, dose-level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once weekly subcutaneous injection of ACP-001</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Human Growth Hormone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Once daily subcutaneous injection of human Growth Hormone (rhGH)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACP-001</intervention_name>
    <description>Once weekly subcutaneous injection</description>
    <arm_group_label>ACP-001, dose-level 1</arm_group_label>
    <arm_group_label>ACP-001, dose-level 2</arm_group_label>
    <arm_group_label>ACP-001, dose-level 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Human Growth Hormone</intervention_name>
    <description>Once daily subcutaneous injection of human Growth Hormone</description>
    <arm_group_label>Human Growth Hormone</arm_group_label>
    <other_name>Somatropin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Prepubertal children, Tanner stage 1

          -  Diagnosis of GHD, confirmed by two stimulation tests

          -  Bon age not greater than chronological age

          -  Impaired height and height velocity

          -  BMI within +/- 2 SD

          -  Baseline IGF-I

          -  Normal fundoscopy

          -  Stable hormonal replacement therapy (other than hGH)

          -  Written Informed Consent

        Exclusion Criteria:

          -  Prior exposure to rhGH or IGF-I

          -  Past or present intracranial tumor; history or presence of malignant disease

          -  Small for gestational age (SGA)

          -  Malnutrition

          -  Psychosocial dwarfism

          -  Coeliac disease

          -  Anti-hGH antibodies

          -  Diabetes mellitus

          -  Chromosomal abnormalities (e.g. Turner syndrome, SHOX)

          -  Closed epiphyses

          -  Known or suspected HIV infection
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre Chatelain, Prof, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Lyon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Beckert, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ascendis Pharma A/S</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Beckert, MD</last_name>
    <phone>+4536944486</phone>
    <email>mb@ascendispharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Leipzig</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Budapest</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Pecs</name>
      <address>
        <city>Pecs</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Szeged</name>
      <address>
        <city>Szeged</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Samara</name>
      <address>
        <city>Samara</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Ufa</name>
      <address>
        <city>Ufa</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 18, 2013</lastchanged_date>
  <firstreceived_date>June 3, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Human Growth Hormone</keyword>
  <keyword>rhGH</keyword>
  <keyword>hGH</keyword>
  <keyword>GHD</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dwarfism, Pituitary</mesh_term>
    <mesh_term>Endocrine System Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
